Khoshnood S, Fathizadeh H, Neamati F, Negahdari B, Baindara P, Abdullah M
Front Oncol. 2022; 12:953678.
PMID: 36158673
PMC: 9491211.
DOI: 10.3389/fonc.2022.953678.
Kreitman R, Pastan I
Biomolecules. 2021; 11(11).
PMID: 34827694
PMC: 8615697.
DOI: 10.3390/biom11111696.
MacDonald A, Wu T, Hung C
J Immunol Res. 2021; 2021:7855808.
PMID: 34790830
PMC: 8592747.
DOI: 10.1155/2021/7855808.
Sugaya M
Int J Mol Sci. 2021; 22(20).
PMID: 34681738
PMC: 8537763.
DOI: 10.3390/ijms222011079.
Robles-Oteiza C, Ayeni D, Levy S, Homer R, Kaech S, Politi K
Dis Model Mech. 2021; 14(11).
PMID: 34494649
PMC: 8617309.
DOI: 10.1242/dmm.049072.
Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.
Hamamichi S, Fukuhara T, Hattori N
Toxins (Basel). 2020; 12(10).
PMID: 33076544
PMC: 7602748.
DOI: 10.3390/toxins12100658.
Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman R, Pastan I
Biomolecules. 2020; 10(8).
PMID: 32756468
PMC: 7464581.
DOI: 10.3390/biom10081140.
Targeted Diphtheria Toxin-Based Therapy: A Review Article.
Shafiee F, Aucoin M, Jahanian-Najafabadi A
Front Microbiol. 2019; 10:2340.
PMID: 31681205
PMC: 6813239.
DOI: 10.3389/fmicb.2019.02340.
Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.
Kumar P, Kumar A, Parveen S, Murphy J, Bishai W
Immunotherapy. 2019; 11(13):1117-1128.
PMID: 31361167
PMC: 7006781.
DOI: 10.2217/imt-2019-0060.
Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome.
Oka T, Miyagaki T
Front Med (Lausanne). 2019; 6:116.
PMID: 31192214
PMC: 6548851.
DOI: 10.3389/fmed.2019.00116.
Immunological effects of everolimus in patients with metastatic renal cell cancer.
Huijts C, Santegoets S, de Jong T, Verheul H, de Gruijl T, van der Vliet H
Int J Immunopathol Pharmacol. 2017; 30(4):341-352.
PMID: 28988508
PMC: 5806813.
DOI: 10.1177/0394632017734459.
DABIL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice.
Bhopale M, Hilliard B, Constantinescu C, Phillips S, Rostami A
Immunopharmacol Immunotoxicol. 2017; 39(6):318-329.
PMID: 28929835
PMC: 5705025.
DOI: 10.1080/08923973.2017.1369099.
Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.
Baldo B
Drug Saf. 2015; 38(5):455-79.
PMID: 25832756
DOI: 10.1007/s40264-015-0285-9.
Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak on CD25 cells.
Lutz M, Baur A, Schuler-Thurner B, Schuler G
Oncoimmunology. 2014; 3:e28223.
PMID: 25050193
PMC: 4091105.
DOI: 10.4161/onci.28223.
Cross-study homogeneity of psoriasis gene expression in skin across a large expression range.
Bigler J, Rand H, Kerkof K, Timour M, Russell C
PLoS One. 2013; 8(1):e52242.
PMID: 23308107
PMC: 3537625.
DOI: 10.1371/journal.pone.0052242.
Advanced-stage primary cutaneous T-cell lymphoma treated with bexarotene and denileukin diftitox.
Cervigon-Gonzalez I, Torres-Iglesias L, Palomo-Arellano A, Gil-Pascual B
Case Rep Dermatol. 2011; 3(1):13-7.
PMID: 21931572
PMC: 3175357.
DOI: 10.1159/000324185.
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Lansigan F, Stearns D, Foss F
Cancer Manag Res. 2010; 2:53-9.
PMID: 21188096
PMC: 3004568.
DOI: 10.2147/cmar.s5009.
Essential lysine residues within transmembrane helix 1 of diphtheria toxin facilitate COPI binding and catalytic domain entry.
Trujillo C, Taylor-Parker J, Harrison R, Murphy J
Mol Microbiol. 2010; 76(4):1010-9.
PMID: 20398220
PMC: 4113555.
DOI: 10.1111/j.1365-2958.2010.07159.x.
Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Kaminetzky D, Hymes K
Biologics. 2009; 2(4):717-24.
PMID: 19707452
PMC: 2727893.
DOI: 10.2147/btt.s3084.
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Kreitman R
Curr Pharm Des. 2009; 15(23):2652-64.
PMID: 19689336
PMC: 6321767.
DOI: 10.2174/138161209788923949.